Patricia Fox1, Andrew Darley2, Eileen Furlong2, Christine Miaskowski3, Elisabeth Patiraki4, Jo Armes5, Emma Ream6, Constantina Papadopoulou7, Lisa McCann7, Nora Kearney8, Roma Maguire7. 1. UCD School of Nursing, Midwifery and Health Systems, Health Sciences Centre, Belfield, Dublin 4, Ireland. Electronic address: patricia.fox@ucd.ie. 2. UCD School of Nursing, Midwifery and Health Systems, Health Sciences Centre, Belfield, Dublin 4, Ireland. 3. Department of Physiological Nursing, University of California, San Francisco, CA 94143-0610, United States. 4. Papadiamantopoulou 123, 11527 Goudi, Athens, Greece. 5. Florence Nightingale SchNM, James Clerk Maxwell Building, Waterloo, United Kingdom. 6. University of Surrey, School of Health Sciences, Faculty of Health and Medical Sciences, Guildford, Surrey, GU2 7XH, United Kingdom. 7. University of Surrey School of Health Sciences, Faculty of Health & Medical Sciences, Standard Buildings, Office 2.4, 2nd Floor, 94 Hope Street Glasgow, G2 6PH, United Kingdom. 8. University of Surrey, Faculty of Health and Medical Sciences, Duke of Kent Building, Guildford, Surrey, GU2 7XH, United Kingdom.
Abstract
PURPOSE: The purpose of the eSMART (Electronic Symptom Management using the Advanced Symptom Management System (ASyMS) Remote Technology) study is to evaluate the use of mobile phone technology to manage chemotherapy-related toxicities (CRTs) in people with breast cancer (BC), colorectal cancer (CRC), Hodgkin's lymphoma (HL), and non-Hodgkin lymphoma (NHL)) across multiple European sites. One key objective was to review the published and grey literature on assessment and management of CRTs among patients receiving primary chemotherapy for BC, CRC, HL, and NHL to ensure that ASyMS remained evidence-based and reflected current and local practice. METHODS: Three electronic databases were searched for English papers, with abstracts available from 01/01/2004-05/04/2014. For the grey literature, relevant clinical practice guidelines (CPGs)/evidence-based resources (EBRs) from the main international cancer organisations were reviewed as were symptom management (SM) protocols from the sites. RESULTS: After full-text screening, 27 publications were included. The majority (n = 14) addressed fatigue and focused on BC patients. Relevant CPGs/EBRs were found for fatigue (n = 4), nausea/vomiting (n = 5), mucositis (n = 4), peripheral neuropathy (n = 3), diarrhoea (n = 2), constipation (n = 2), febrile neutropenia/infection (n = 7), palmar plantar erythrodysesthesia (PPE) (n = 1), and pain (n = 4). SM protocols were provided by >40% of the clinical sites. CONCLUSIONS: A need exists for empirical research on SM for PPE, diarrhoea, and constipation. Research is needed on the efficacy of self-care strategies in patients with BC, CRC, HL, and NHL. In general, consistency exists across CPGs/EBRs and local guidelines on the assessment and management of common CRTs.
PURPOSE: The purpose of the eSMART (Electronic Symptom Management using the Advanced Symptom Management System (ASyMS) Remote Technology) study is to evaluate the use of mobile phone technology to manage chemotherapy-related toxicities (CRTs) in people with breast cancer (BC), colorectal cancer (CRC), Hodgkin's lymphoma (HL), and non-Hodgkin lymphoma (NHL)) across multiple European sites. One key objective was to review the published and grey literature on assessment and management of CRTs among patients receiving primary chemotherapy for BC, CRC, HL, and NHL to ensure that ASyMS remained evidence-based and reflected current and local practice. METHODS: Three electronic databases were searched for English papers, with abstracts available from 01/01/2004-05/04/2014. For the grey literature, relevant clinical practice guidelines (CPGs)/evidence-based resources (EBRs) from the main international cancer organisations were reviewed as were symptom management (SM) protocols from the sites. RESULTS: After full-text screening, 27 publications were included. The majority (n = 14) addressed fatigue and focused on BC patients. Relevant CPGs/EBRs were found for fatigue (n = 4), nausea/vomiting (n = 5), mucositis (n = 4), peripheral neuropathy (n = 3), diarrhoea (n = 2), constipation (n = 2), febrile neutropenia/infection (n = 7), palmar plantar erythrodysesthesia (PPE) (n = 1), and pain (n = 4). SM protocols were provided by >40% of the clinical sites. CONCLUSIONS: A need exists for empirical research on SM for PPE, diarrhoea, and constipation. Research is needed on the efficacy of self-care strategies in patients with BC, CRC, HL, and NHL. In general, consistency exists across CPGs/EBRs and local guidelines on the assessment and management of common CRTs.
Authors: Roma Maguire; Lisa McCann; Grigorios Kotronoulas; Nora Kearney; Emma Ream; Jo Armes; Elisabeth Patiraki; Eileen Furlong; Patricia Fox; Alexander Gaiger; Paul McCrone; Geir Berg; Christine Miaskowkski; Antonella Cardone; Dawn Orr; Adrian Flowerday; Stylianos Katsaragakis; Andrew Darley; Simone Lubowitzki; Jenny Harris; Simon Skene; Morven Miller; Margaret Moore; Liane Lewis; Nicosha DeSouza; Peter T Donnan Journal: BMJ Date: 2021-07-21
Authors: Helena Harder; Valerie M Shilling; Shirley F May; David Cella; Peter Schmid; Lesley J Fallowfield Journal: Breast Cancer Res Treat Date: 2020-07-27 Impact factor: 4.872
Authors: Katarína Hradská; Tereza Popková; Michaela Skořupová; Jana Mihályová; Tomáš Jelínek; Jana Lančová; Norbert Schellong; Roman Hájek Journal: Cancer Manag Res Date: 2022-05-04 Impact factor: 3.602
Authors: Angel Charles; Christopher M Bourne; Tanya Korontsvit; Zita E H Aretz; Sung Soo Mun; Tao Dao; Martin G Klatt; David A Scheinberg Journal: Oncoimmunology Date: 2021-05-24 Impact factor: 8.110